一圖看懂高視醫療(2407.HK)IPO
高視醫療(2407.HK)於11月30日至12月5日招股,公司擬全球發售約1307萬股股份。其中香港發售股份數目約爲131萬股,國際發售股份數目約爲1176萬股。招股價爲51.4港元每股,每手100股,一手入場費約爲5191.81港元,預計將於12月12日在港交所上市。聯席保薦人爲摩根士丹利和海通國際。
據悉,高視醫療是中國一家全面的眼科醫療器械提供商。其產品組合廣泛涵蓋眼科醫療器械用於診斷、治療或手術的所有7個眼科亞專科。根據弗若斯沙利文的資料,高視醫療憑藉着6.7%的市場份額,成爲中國眼科醫療器械市場最大的國內參與者。按2021年的收入計,高視醫療爲包括外資企業在內的第四大參與者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.